ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 2608

Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis

Maria Dons1, Charlotte Näslund-Koch2, Morten Sengeløv3, Sofie Bøgh-Sørensen3, Kristoffer Skaarup3, Marianne Bengtson Løvendorf4, Filip Davidovski3, Anne Marie Reimer Jensen3, Brittany Weber5, Lise Lotte Gluud6, Claus Zachariae2, Lone Skov2 and Tor Biering-Sørensen3, 1Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, 2Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, 3Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, 4Department of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, 5Brigham and Women's Hospital, DEDHAM, MA, 6Gastro Unit, Copenhagen University Hospital – Hvidovre, Copenhagen, Hovedstaden, Denmark

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Cardiovascular, Dermatology, prevention, Psoriatic arthritis

Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: ARP II: Perception, Prediction, and Prevention (2603–2608)

Session Type: Abstract Session

Session Time: 4:15PM-4:30PM

Background/Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic risk factor. Individuals with psoriasis have a high prevalence of MASLD, yet the association between MASLD and cardiac manifestations in this population remains unclear.
We aimed to evaluate associations between MASLD, cardiovascular risk factors, and cardiac structure and function in adults with psoriasis.

Methods: A total of 261 adults with psoriasis were consecutively enrolled in the PSOCADIA study (Prevalence and risk factors asSOciated with CArdiac comorbiDIty in psoriAsis, ClinTrials.gov: NCT04950218) from the Copenhagen Translational Skin Immunology Biobank and Research Programme (BIOSKIN). Participants underwent clinical assessment, transthoracic echocardiography, transient elastography (TE), and blood withdrawal. MASLD was defined as hepatic steatosis on TE with controlled attenuation parameter ³ 250 dB and presence of ³ 1 cardiometabolic risk factor(s), excluding other causes of liver disease. Measures of cardiac structure and function were compared between psoriasis patients with MASLD and those without MASLD. Associations between MASLD, diastolic and systolic dysfunction were assessed in uni- and multivariable regression models.

Results: We prospectively enrolled 261 individuals with psoriasis (median age 53.5 years, 46.4% women), whereof 20.7% had psoriatic arthritis. MASLD was present in 90 patients (34.5%) of whom 7 (8%) had possible advanced fibrosis. Compared to individuals without MASLD, those with MASLD exhibited higher blood pressure, higher body mass index (BMI), and more adverse cardiometabolic profiles including more prevalent diabetes (14.4% vs. 1.9%, p < 0.001). MASLD was associated with structural measures indicative of cardiac hypertrophy and worse measures of diastolic and systolic function. However, after adjusting for age, sex, and BMI, these associations were no longer statistically significant. In fully adjusted models, MASLD was not associated with diastolic or systolic dysfunction. In contrast, higher BMI and diabetes remained independently associated with myocardial dysfunction.

Conclusion: In adults with psoriasis, associations between MASLD and abnormal cardiac structure and function were attenuated after adjustment for cardiometabolic risk factors, underscoring the importance of risk factor control in individuals with psoriasis and concomitant MASLD. This may also reflect that most adults with psoriasis and MASLD did not have hepatic fibrosis in this cohort.

Supporting image 1Cardiometabolic risk factors and myocardial dysfunction in adults with psoriasis with and without MASLD. A) Distribution of the number of cardiometabolic risk factors and B) Prevalence of diastolic and systolic dysfunction in individuals with psoriasis with and without MASLD. Bars represent the proportion of individuals (%) within each group. Cardiometabolic risk factors included obesity, hypertension, dyslipidemia, diabetes, and metabolic syndrome.

Abbreviations: MASLD, metabolic dysfunction-associated liver disease.

Supporting image 2Association between MASLD and cardiac structure and function in A) uni- and B) multivariable models adjusted for age, sex, and BMI. Mean differences (x-axis) in echocardiographic measures of cardiac structure, diastolic and systolic function (y-axis) in MASLD compared to no MASLD in the study population. Mean differences plotted with 95% confidence intervals in A) univariable linear regression models and B) multivariable linear regression models adjusted for age, sex, and BMI.

Abbreviations: IVSd, Interventricular septum diameter; LVPWd, Left ventricular posterior wall diameter; LVMi, Left ventricular mass index; RWT, Relative wall thickness; LAVi, Left atrial volume index; MV E, Mitral valve early filling velocity; MV A, Mitral valve atrial contraction velocity; E/A, Ratio of early to late mitral inflow velocities; e’, Early diastolic mitral annular velocity; E/e’, Ratio of early mitral inflow to mitral annular velocity; TR Vmax, Tricuspid regurgitation peak velocity; LVEF, Left ventricular ejection fraction; GLS, Global longitudinal strain.

Supporting image 3Associations between MASLD, cardiometabolic risk factors and myocardial dysfunction in psoriasis. Uni- and multivariable associations between risk factors and diastolic and systolic dysfunction. Forest plots display odds ratios (OR) for diastolic dysfunction (left panels) and systolic dysfunction (right panels) on logarithmic scale with 95% confidence intervals for MASLD and other key cardiometabolic risk factors. Top panels show univariable models for each risk factor, while bottom panels show fully adjusted models for age, sex, and all risk factors.

Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; MetS, metabolic syndrome.


Disclosures: M. Dons: Karen Elise Jensens Foundation, 5, Lundbeck Foundation, 5; C. Näslund-Koch: AbbVie/Abbott, 12, Investigator, CSL Behring, 12, Investigator, Danish National Psoriasis Foundation, 5, Ellab Foundation, 5, Galderma, 12, Investigator, Kgl. Hofbundtmager Aage Bang Foundation, 5, Krista and Viggo Petersens Foundation, 5, LEO foundation, 2, 5, 6, LEO Pharma, 12, Investigator, Novartis, 12, Investigator, Siemens Healthcare, 5, UCB, 6; M. Sengeløv: None; S. Bøgh-Sørensen: None; K. Skaarup: None; M. Løvendorf: None; F. Davidovski: None; A. Jensen: None; B. Weber: Bristol-Myers Squibb(BMS), 2, Kiniksa Pharmaceuticals, 2, Novo nordisk, 2, Novo Nordisk, 2, Oruka, 2; L. Gluud: AstraZeneca, 1, 2, Beckton Dickinson, 2, Boehringer-Ingelheim, 1, 2, Ipsen, 12, Support for attending meetings and/or travel, Novo Nordisk, 1, 2, 5, 6, Sobi International, 5; C. Zachariae: None; L. Skov: AbbVie/Abbott, 1, 6, Almirall, 1, 5, Bristol-Myers Squibb(BMS), 1, 5, 6, Eli Lilly, 1, 6, Janssen, 1, 5, 6, Novartis, 1, Pfizer, 6, Sanofi, 1, 5, 6, stada, 1, takeda, 1, 6, UCB, 1, 5, 6; T. Biering-Sørensen: Amgen, 2, AstraZeneca, 5, 6, Bayer, 6, Boston Scientific, 5, CSL Seqirus, 2, GE Healtcare, 5, 6, GlaxoSmithKlein(GSK), 2, 5, 6, IQVIA, 2, Novartis, 5, 6, Novo Nordisk, 2, 5, Parexel, 2, Pfizer, 5, Sanofi Pasteur, 2, 5, 6.

To cite this abstract in AMA style:

Dons M, Näslund-Koch C, Sengeløv M, Bøgh-Sørensen S, Skaarup K, Løvendorf M, Davidovski F, Jensen A, Weber B, Gluud L, Zachariae C, Skov L, Biering-Sørensen T. Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/metabolic-dysfunction-associated-steatotic-liver-disease-cardiometabolic-risk-factors-and-cardiac-manifestations-in-psoriasis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/metabolic-dysfunction-associated-steatotic-liver-disease-cardiometabolic-risk-factors-and-cardiac-manifestations-in-psoriasis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology